Weekend Update - W2624
▶ Explore this week’s Tape — live, sortable, drill-down →Good News, Sold: The AI Buildout’s First Bill Came DueEvery capital cycle has the same tell. It is not the day the spending stops. It is the day the market stops clapping for it — when a company does exactly what it promised and the stock falls anyway. This week the most expensive trade on earth hit that day three times.Oracle delivered the backlog it told everyone it would deliver. A six-hundred-thirty-eight-billion-dollar pile of contracted future revenue, up more than three-and-a-half times in a year.¹ Cloud infrastructure revenue up ninety-three percent.² It did the thing. The stock fell ten percent.³For two years the AI trade was a referendum on demand: is it real, how big, how fast. The bull won that argument. So the market moved the goalposts, the way it always does at this point in a buildout — from is the demand there to who pays to meet it, and what does the bill do to the balance sheet carrying it. Bill Maris said the quiet part on All-In this week: a trillion dollars of spend commitments sitting on sixty billion of revenue, and now you go to the public markets and hope retail picks up the difference.⁴ That is the bear case in one sentence. Three names walked straight into it this week, and the interesting part is that each of them is paying the bill a different way.Oracle is borrowing it. Trailing free cash flow is already negative — they spent the better part of fifty billion dollars on capex to build the capacity behind that backlog, and the money to fund the next leg is coming out of the debt market into a tape that has stopped rewarding capital plans.⁵ NextEra is diluting for it. The biggest bet in the history of regulated utilities — a sixty-seven-billion-dollar, all-stock takeover of Dominion, built explicitly to wire thirty gigawatts of data-center power by twenty-thirty-five, Google and Meta already signed.⁶ All-stock is the tell. A utility already carrying sixteen times debt to free cash flow cannot borrow its way to the biggest deal in its sector’s history, so it is paying with equity and handing the cost to the shareholder it already has.⁷ The stock fell nine percent.⁸ Micron is the one name pre-selling it: its entire next fiscal year of high-bandwidth memory is already spoken for, certified into Nvidia’s roadmap, the demand contracted before the capacity ships.⁹Three funding strategies — debt, equity, pre-sold demand — and one underlying wager: that AI demand is durable enough to convert all of it to cash before the interest comes due. The cashflow read is in Marcus’s column below; short version, two of these three have no multiple to quote because the denominator is still negative. Page one of the Cash Flow Memo this week is a capex ledger, not an earnings sheet.This is what the back half of a capital cycle looks like, and it rhymes. The railroads, the fiber glut, the shale decade — the capital cycle never turns when the building stops. It turns when the market stops paying for the announcement and starts pricing the lag between the spend and the cash. The demand did not get worse this week. The accounting for it did.The next data point is dated. Micron reports Wednesday the twenty-fourth.¹⁰ On the screen it trades at a hundred times trailing free cash flow, which sounds insane and tells you nothing — that is trough cash flow at the bottom of a memory cycle. Price it forward and consensus has it at a single-digit multiple of next year’s earnings,¹¹ with trailing cash flow already up more than five-fold off the low.¹² The test is not the headline print. It is whether the forward demand the whole buildout is leaning on shows up in one company’s order book. If Micron’s guide confirms, the bill looks affordable. If it wobbles, the cycle just got more expensive for all three.Wall Street’s consensus on the AI buildout: too crowded, too expensive, too late. The stocks fell this week not because the demand soured — because the market finally started counting the cost. That is not the top. That is the capital cycle clearing its throat.The Tape — W2624Universe of 94 cashflow-memo names, snap dates 2026-06-05 → 2026-06-15. Composite is rank-sum percentile of FCF Yield + NTM Revenue Growth (higher = better balance). Banks and finance-book names shown separately.Telltales Yield — Top 10From the Cashflow Desk — Marcus GrahamHealthcare spent the week getting repriced by Washington, and the screens are tarring the whole sector with one brush. Regeneron is the name that brush gets wrong. It sits near the top of the board at 11.3x EV/FCF on an 8.8% free cash flow yield — cheaper than UnitedHealth, with no federal prosecutor auditing the numerator. That is the distinction the table cannot draw: UNH’s cash engine is the thing the DOJ is investigating; Regeneron’s is a drug franchise nobody has subpoenaed. Same sector, same de-rate, two completely different reasons for the cheap — one is cheap because the cash might be fiction, the other because it shares a GICS code with the one that might be. The test on the next print is whether biosimilar pressure on the franchise shows up in the cash line, or the de-rate was just guilt by association.Telltales Yield — Bottom 10This Week’s ReportersSector MediansDebt / FCF Watch (highest leverage on TTM FCF)Weekly Price MovementTop 5 (week-over-week price) Bottom 5 (week-over-week price) Banks (shown separately — FCF metric not meaningful)Finance-book — FCF not comparableCustomer-float / captive-finance / reserve businesses (IBKR broker float, KMX CarMax Auto Finance, PYPL customer funds, CRCL stablecoin reserves). The memo’s operating-FCF method overstates their FCF, so they are held off the ranked leaderboard pending the P&L-waterfall rebuild. Data Gaps90 of 90 ranked-eligible names ranked. 0 dropped for missing FCF yield or NTM revenue growth; 7 shown separately (banks + finance-book, FCF not comparable).Source: cashflow-memo master_2026-06-15.csv. NTM growth from FMP analyst-estimates consensus. Composite is a percentile rank, not a recommendation.The Issue — This Week's BriefThe Cashflow MemoWhen Cheap Stopped Being SafeThe week being cheap stopped being safe, and the AI buildout kept spending anyway.The Telltales Weekend Update. Ava Cabot and analyst Marcus Graham walk through what happened this week — and what’s coming next — across the universe of the Cash Flow Memo. About 13 minutes. No filler.Download the memo at telltales.us. Hunt, Jason, and Mike are back Wednesday on episode 2625.Chapter markers* Time | Segment* 0:15 | Cold open* 0:55 | Theme — the AI buildout’s bill: Oracle, NextEra, Micron* 5:10 | Deep dive — UnitedHealth vs CarMax* 9:25 | Rapid-fire — Moderna, Intel* 11:30 | Close + Consensus WatchFull transcriptOpening disclaimerAva: The following conversation is intended for informational purposes only. You should always do your own work to determine if an investment is suitable for you.Cold openAva: You’re listening to the Telltales Weekend Update. I’m Ava Cabot.Marcus: And I’m Marcus Graham — the cashflow desk.Ava: Quick note: the show is produced entirely with AI tools, and both voices you’re hearing are AI-generated. Send feedback through the Substack. We’re still early — this is a pilot, and we want to hear what’s working.Ava: Here’s the week. Being cheap stopped being safe. The cheapest large-cap in healthcare spent the week with a federal prosecutor at the door. The retail name everyone screens as cheap is being handed customers by a tariff. And while the market was busy repricing the cheap stuff, the most expensive trade on earth — the AI buildout — just kept writing bigger and bigger checks, and got punished for it anyway. On Wednesday’s main show, episode 2624, Hunt, Jason, and Mike worked through the economics of that buildout — the data centers, and the sheer physics of powering them.[^ep-e2624] We’re going to put the cashflow lens on the bill. Because this was the week the bill started showing up in three different places at once.Theme — the AI buildout’s billAva: Start with the most expensive trade in the market, because this week it got complicated. For two years the AI story was demand — is it real, how big, how fast. This week the question flipped to cost. Who delivers it, who powers it, and whose balance sheet carries it. And here’s the contrarian note hanging over the whole thing: as Bill Maris put it on All-In this week, quote, a trillion in spend commitments on $60 billion of revenue, and now you’re going to go to the public and hope that retail is going to pick that up.[^tp-maris-allin-20260609] Hold that thought. Because three companies just tested it.Ava: Start with Oracle, because it did exactly what it promised and got punished for it. It delivered the backlog it said it would — and the stock fell 10% anyway.[^orcl-stock-20260610] Page 2 of the memo: remaining performance obligations hit a record $638 billion, up 363% year over year.[^orcl-rpo-20260610] Cloud infrastructure revenue up 93%.[^orcl-oci-growth-20260610] They did the thing. Marcus — why did doing the thing get them sold?Marcus: Because the market stopped grading the backlog and started grading the bill. Oracle’s trailing free cash flow is negative — minus $21 billion[^memo-orcl-fcf-20260615] — because they spent $48 billion on capex over the last year to build the capacity behind that backlog.[^memo-orcl-capex-20260615] So there’s no multiple to quote. Don’t reach for one; it’s a negative number. What prices Oracle now is one question: does $638 billion of contracted intent convert to cash before the interest on the build eats them. They raised the capital plan into a tape that no longer claps for capital plans. Maris’s line is the bear case in one sentence — and Oracle just walked straight into it.Ava: So next door, the power bill. NextEra just made the biggest bet in the history of regulated utilities — and got the same treatment Oracle did. A $67 billion, all-stock takeover of Dominion Energy, the largest regulated-utility deal ever, built explicitly to power AI data centers — 30 GW of it by 2035, with Google and Meta already signed on.[^nee-dominion-acquisition-20260610][^nee-datacenters-expansion-20260615] The stock fell 9%.[^nee-stock-decline-20260610] Marcus, what does the grid cost?Marcus: It costs more than NextEra has. This is a utility that already carries 16x debt to free cash flow[^memo-nee-debtfcf-20260615] — and it’s buying the biggest deal in the sector’s history. They’re paying in stock, not debt, which is the tell: they’re funding the buildout by diluting, because the balance sheet can’t borrow its way there at 41x free cash flow.[^memo-nee-evfcf-20260615] The 9% drop isn’t the market rejecting data-center power. It’s the market asking who eats the cost of building it — and deciding, this week, that the answer is the existing shareholder.Ava: And the third bill is memory, where Wall Street has completely lost its composure. Micron, page 5, reports a week from Wednesday — and ahead of it, price targets went from $550 to $1,750 in a matter of days.[^mu-pt-raise-20260608][^mu-analyst-targets-20260610] Micron got certified for Nvidia’s next-generation HBM4 memory, and its entire fiscal-year production is already spoken for.[^mu-hbm4-cert-20260610] One more tell you won’t see in the price: the Talnexis hiring tracker shows Micron added 200 roles last week, hiring at full-cycle pace.[^tlnx-mu-hiring-20260615] Marcus, the stock screens at 100x cash flow — is that insane?Marcus: It looks insane and it isn’t, and that’s the whole trick with memory. The 100x figure is trailing free cash flow at the bottom of the cycle[^memo-mu-evfcf-20260615] — it tells you nothing. Price it forward: consensus earnings put Micron at about 7x next fiscal year.[^mu-fwd-pe-20260615] Trailing cash flow is already up more than 5x off the trough, and revenue is guided to grow 60%+.[^memo-mu-fcf-20260615] You don’t value a cyclical on a trough multiple; you value it on where the cash is going — and forward, this is a single-digit multiple. The risk isn’t the price. The risk is that the whole supercycle thesis — Oracle’s backlog, NextEra’s gigawatts, Micron’s HBM — is one connected bet that the AI demand is durable. Three names, one wager. The print on the 24th is the next data point on whether it holds.Deep dive — UnitedHealth vs CarMaxAva: Now the other half of the market — the cheap half. Two companies, both trading at single-digit-ish multiples, both cheap for a reason, and the reasons could not be more opposite. One is being investigated by the government for charging too much. The other is being handed customers by the government’s tariffs. Same week, two service businesses, two completely different verdicts on what cheap means.Ava: Here are the headlines, side by side. UnitedHealth, all the way back on page 19 of the memo: the CEO, Andrew Witty, resigned; the company pulled its full-year guidance; and the Justice Department opened a criminal and civil probe into whether it inflated Medicare diagnoses to juice reimbursements.[^unh-ceo-resignation-20260615][^unh-guidance-pull-20260615][^unh-doj-probe-20260615] The stock is down about a third from its high.[^unh-stock-recovery-20260615] And CarMax, page 8, reports Wednesday — first print under a new CEO, with an activist on the register, into a tariff backdrop that’s pushing buyers out of new cars and straight onto its lots.[^kmx-cfo-transition-20260615][^kmx-activist-20260615][^kmx-tariffs-20260615] Marcus — which kind of cheap actually pays you?Marcus: Take the scary one first. UnitedHealth trades at 14x trailing free cash flow, a 7% yield.[^memo-unh-evfcf-20260615] On the screen that’s the cheapest quality compounder in the market. Here’s the problem: the thing generating the cash is exactly what the DOJ is investigating. The free cash flow comes from Medicare Advantage billing, and a federal prosecutor is now asking whether that billing was fraudulent.[^unh-doj-probe-20260615] So you’re not buying 14x earnings. You’re buying 14x a number that’s under subpoena. Cheap doesn’t help you when the regulator is auditing the numerator.Ava: And yet the stock just rebounded almost back to its high. Make that make sense.Marcus: It doesn’t, and that’s the tell. In the same two weeks the probe widened, six different shops raised their price targets — and Bank of America went the other way and cut it to neutral.[^unh-analyst-upgrade-20260615][^unh-bofa-downgrade-20260615] So the sell-side is openly split on the same name in the same fortnight. That’s not a market pricing a verdict. It’s a market pricing a coin flip on whether a federal probe breaks the cash engine or just dents it. When the analysts can’t agree which, the multiple isn’t cheap — it’s unresolved.Ava: So UnitedHealth’s cheap is a question mark. What’s CarMax’s cheap?Marcus: Cheaper on the screen than in the business. Price CarMax on earnings and it’s a mid-teens multiple — about 15x forward,[^kmx-fwd-pe-20260615] a normal retailer, not a coiled spring. So the bet was never the multiple. It’s the setup: tariffs added thousands of dollars to new-car prices, used demand is the spillover, and there’s an activist pushing the new CEO to convert it.[^kmx-tariffs-20260615] The test on Wednesday is one number — used unit volume. If that’s accelerating, the multiple re-rates. If it’s flat, it’s just a tired retailer at 15x.Ava: So one cheap stock where the earnings might be fiction, and one that’s barely cheap once you do the math. Marcus, ever the optimist.Marcus: I deal in denominators. But the asymmetry is real: UnitedHealth’s downside is a business model the government breaks; CarMax’s downside is a soft quarter. One is binary. The other is just cyclical. Same word — cheap — two completely different bets.Ava: Mark the calendar. Wednesday tells us which one.Rapid-fireAva: Two more to close, both moving fast.Ava: Moderna got a different kind of government attention — the bad kind. Health and Human Services terminated a $590 million contract for Moderna’s bird-flu vaccine, and cancelled 22 more mRNA research contracts across the board, under the new RFK Jr. vaccine policy.[^mrna-barda-birdfly-20260610][^mrna-barda-platform-shift-20260610] There’s an FDA advisory meeting Wednesday on an mRNA flu shot.[^mrna-fda-advisory-20260618] This is the same theme as UnitedHealth from the other direction — Washington isn’t just regulating healthcare this year, it’s picking which platforms live. mRNA just got told it’s on the wrong list.Ava: And Intel — remember Intel? Up 250% this year, and almost nobody noticed.[^intc-ytdperformance-20260615] The catalyst this week: Google committed more than 3 million of its TPU chips to Intel’s foundry for 2028, pulling that order away from Taiwan Semi.[^intc-google-tpu-20260608] Bank of America double-upgraded the stock straight from sell to buy.[^intc-bofaupgrade-20260611] After a decade of being the company the buildout left behind, Intel spent this week being the company the buildout came back to.CloseAva: That’s the show. Wall Street’s consensus this week: UnitedHealth is a falling knife, and the AI infrastructure names are crowded. One of those is wrong, and it’s the one nobody wants to touch. Here’s the throughline into Monday: being cheap stopped being safe this week, because the thing setting the price wasn’t the business — it was the government on one side and the buildout’s bill on the other. UnitedHealth at 14x with a prosecutor. CarMax at mid-teens with a tariff at its back. Oracle, NextEra, and Micron spending into the doubt. Cheap got cheaper, expensive kept spending, and the market spent the week deciding it doesn’t trust either one. The hiring data we cited on Micron is from Talnexis — talnexis.com. You can pull up the Cash Flow Memo yourself at telltales.us. The forward week is loaded: CarMax reports Wednesday, FedEx the following Tuesday in its first quarter as a pure-play after spinning off freight,[^earn-fdx] and Micron Wednesday the 24th.[^earn-mu] And Hunt, Jason, and Mike are back Wednesday on episode 2625. We’ll see you next Saturday.Closing disclaimerAva: The views expressed on this podcast are the host alone and do not constitute an offer to sell or a recommendation to purchase, or a solicitation of an offer to buy any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the host nor any of their employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness, or completeness of this information. The host and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future, and may or may not hold positions in the securities mentioned.Sources* Applied Clinical Trials Online. (2026, June). HHS cancellation of BARDA mRNA vaccine trial. https://www.appliedclinicaltrialsonline.com/view/hhs-cancellation-barda-mrna-vaccine-trial-design-oversight-funding* Bank of America via TipRanks. (2026, June). UnitedHealth downgraded to Neutral at BofA amid Medicare Advantage uncertainty. https://www.tipranks.com/news/the-fly/unitedhealth-downgraded-to-neutral-at-bofa-amid-ma-uncertainty* Converge Digest. (2026, June 10). Oracle’s AI infrastructure business drives 93% IaaS growth. https://convergedigest.com/oracles-ai-infrastructure-business-drives-93-iaas-growth/* Cryptonomist. (2026, June 4). UnitedHealth stock stalls near $377 as lawsuit risk returns. https://en.cryptonomist.ch/2026/06/04/unitedhealth-stock-stalls-near-377-as-lawsuit-risk-returns/* eciks.org. (2026, June 10). NextEra Energy to acquire Dominion Energy in $67 billion all-stock transaction. https://eciks.org/8282-85162-dominion-energy-nextera-67-billion-merger* eMarketer. (2026, June). Auto tariffs are an opportunity for used car dealers. https://www.emarketer.com/content/auto-tariffs-opportunity-used-car-dealers* Fierce Healthcare. (2026, June). DOJ’s criminal probe into UnitedHealth extends to Optum Rx. https://www.fiercehealthcare.com/payers/wsj-report-doj-interviewing-former-employees-about-medicare-billing-practices-unitedhealth* GuruFocus. (2026, June 10). NextEra Energy (NEE) shares decline amid Dominion Energy acquisition. https://www.gurufocus.com/news/8910473/nextera-energy-nee-shares-decline-amid-dominion-energy-acquisition* HeyGo Trade. (2026, June). Intel up 250% in 2026: Is the AI comeback real or a short squeeze? https://www.heygotrade.com/en/blog/intel-stock-2026-ai-comeback/* IndMoney. (2026, June 10). Oracle Q4 FY2026 earnings: Why ORCL stock fell 10% despite a strong beat. https://www.indmoney.com/blog/us-stocks/oracle-q4-fy-2026-earnings-orcl-stock-drop* Interactive Crypto. (2026, June 9). Micron jumps as HBM4 certification and a Wells Fargo $1,220 target reset the narrative. https://www.interactivecrypto.com/micron-jumps-9-9-as-hbm4-certification-and-a-wells-fargo-1-220-target-reset-the-narrative-jun-20* Maris, B. (2026, June 9). Bill Maris: How Google could crush AI competitors, why small funds win, and AI’s Atari stage [Video]. All-In Podcast, YouTube. https://www.youtube.com/watch?v=0umrMuUClC4* MEXC Learn. (2026, May 27–June 8). Wall Street upgraded UNH six times in two weeks (JPMorgan $466, Bernstein $492). https://www.mexc.com/learn/article/wall-street-upgraded-unh-six-times-in-two-weeks-can-unitedhealth-stock-hit-492-unh-price-target-2026-2030/1* The Motley Fool. (2026, June 10). Oracle just revealed a massive $638 billion backlog. Here’s why the stock fell anyway. https://www.fool.com/investing/2026/06/10/oracle-just-revealed-a-massive-638-billion-backlog/* PharmAphorum. (2026, June). UnitedHealth CEO Andrew Witty steps down. https://pharmaphorum.com/news/unitedhealth-ceo-andrew-witty-steps-down* Simply Wall St News. (2026, June). Why CarMax (KMX) is up 8.1% after rising optimism around its 2026 earnings report. https://simplywall.st/stocks/us/retail/nyse-kmx/carmax/news/why-carmax-kmx-is-up-81-after-rising-optimism-around-its-202* TheStreet. (2026, June). Intel stock: BofA raises price target to $135 | INTC. https://www.thestreet.com/investing/stocks/intc-intel-stock-price-target-bank-of-america-june-2026* Timothy Sykes News. (2026, June). CarMax (KMX) draws activist interest as traders eye earnings. https://www.timothysykes.com/news/carmax-inc-kmx-news-2026_06_03/* U.S. Food and Drug Administration. (2026, June 18). Vaccines and Related Biological Products Advisory Committee June 18, 2026 meeting announcement. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-18-2026-meeting-announcement* U.S. Securities and Exchange Commission. (2026). UnitedHealth Group, Form 8-K, Q1 2026. https://www.sec.gov/* Vantage Markets. (2026, June 9). Intel stock up 11%: INTC jumps on Google’s 3M AI chip deal. https://www.vantagemarkets.com/market-analysis/intel-stock-price-analysis-june-9-2026/* Yahoo Finance. (2026, June). NextEra (NEE) anticipates adding up to 30 gigawatts of power for data centers by 2035. https://finance.yahoo.com/news/nextera-nee-anticipates-adding-30-104711159.htmlHiring intelligence* Talnexis. (2026, June 15). Hiring intelligence — Micron (200 new roles in 7 days, #9 hiring-velocity mover). https://www.talnexis.com/Internal dataInternal data is provided on a best efforts basis.Forward earnings (FMP)* KMX — 2026-06-17 (Wednesday), Q1 FY27. FMP /stable/earnings?symbol=KMX, pulled 2026-06-15.* FDX — 2026-06-23 (Tuesday), Q4 FY26 (first pure-play print post freight spin-off). FMP /stable/earnings?symbol=FDX, pulled 2026-06-15.* MU — 2026-06-24 (Wednesday), Q3 FY26, consensus EPS $19.96 / revenue $34.72B. FMP /stable/earnings?symbol=MU, pulled 2026-06-15.* MU forward P/E ≈6.9x — FY ending 2027-08-28 consensus EPS $108.83 (21 analysts) vs price $746.79. FMP analyst estimates (annual), pulled 2026-06-15.* KMX forward P/E ≈15x — FY ending 2027-02-28 EPS $2.35 (17.2x) / FY 2028-02-28 EPS $2.85 (14.2x) vs price $40.34. FMP analyst estimates (annual), pulled 2026-06-15. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com
